
AIM: To explore the efficacy and safety of gonioscopy-assisted transluminal trabeculotomy (GATT) in the treatment of Posner-Schlossman syndrome (PSS). METHODS: A retrospective review was conducted on participants diagnosed with PSS and uncontrolled intraocular pressure (IOP) who underwent GATT between 2023 and 2024. Clinical outcome measures including visual acuity, IOP, gonioscopic findings, complications, and relapses were collected for postoperative visits: 1d, 1wk, 1, 3, 6mo and 1y. RESULTS: Eleven participants (mean age 43.00±13.82y, 5 females and 6 males) were enrolled. Nine participants were followed up for 12mo after the surgery, 1 participant underwent trabeculectomy to decrease the uncontrolled IOP, another participant was followed up for 6mo because of loss of follow-up. The mean IOP before GATT was 33.64±6.21 mm Hg (range: 23–46 mm Hg). The mean number of antiglaucoma medications prior to surgery was 2.73±0.66. At 6mo after the surgery, the mean IOP decreased to 17.36±6.17 mm Hg (47.15%±17.35% reduction). Nine participants were followed up for 12mo, and their mean IOP decreased to 16.22±2.49 mm Hg, with an average IOP reduction of 46.83%±16.93% (P<0.01). The number of anti-glaucoma medications significantly decreased to 0.91±0.83 at the last follow-up (P<0.05). Two eyes were considered treatment failures due to reintervention and uncontrolled IOP. The preoperative IOP of qualified success cases were significantly lower than that of failed cases. The most common complications were intraoperative anterior chamber blood reflux (100%) and IOP spikes (45.45%), both of which resolved within 1wk. During the follow-up period, 7 participants experienced recurrent attacks of PSS. Nevertheless, peak IOP during relapse was significantly reduced compared to preoperative values (P<0.05). CONCLUSION: GATT seems to be a reliable and effective method for the management of PSS with uncontrolled IOP. Higher preoperative IOP maybe the factor of surgical failure. Although it may not prevent relapse of PSS, it might potentially reduce the peak IOP. Longer-term follow-up and a larger sample size are recommended for more in-depth analysis.
AIM: To evaluate the diagnostic utility of meibomian gland uneven atrophy (UA) in identifying Demodex infestation among patients with meibomian gland dysfunction (MGD) and to compare its diagnostic performance with that of cylindrical dandruff (CD). METHODS: Patients with MGD were prospectively enrolled and stratified into four groups (n=25/group) based on the presence/absence of CD and UA. Comparative analyses and multivariate adjustments were performed using Demodex detection confirmed by in vivo confocal microscopy and light microscopy. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis. RESULTS: A total of 100 patients were recruited. The median age was 31.0y (range: 21.0–45.0y; Q1, Q3: 27.0–37.0y), including 29 males and 71 females. Demodex counts per eyelash and positivity rates were highest in the CD+UA+ group, followed by CD+UA−, and CD−UA+, and then CD−UA−. UA was associated with a 5.521-fold increased likelihood of Demodex positivity [95% confidence interval (CI): 2.098–14.531, P=0.001]; CD conferred a 6.460-fold increased risk (95%CI: 2.454–17.002, P<0.001). Incorporating UA status significantly improved model fit (Δχ²=14.096, P<0.001). The areas under the ROC curve (AUC) for CD (in UA–), UA (in CD–), and CD+UA (CD–UA– and CD+UA+) were 0.776, 0.762, and 0.865, respectively. CD and UA demonstrated comparable sensitivity (CD: 87.5%, UA: 86.7%) and specificity (CD: 65.6%, UA: 65.7%), which improved to 90.9% and 82.1%, respectively, when both were combined. CONCLUSION: UA is a significant predictor of Demodex infestation, with diagnostic performance comparable to CD. Combined assessment of CD and UA offers high sensitivity and good specificity, providing a novel and practical tool and substantially reducing misdiagnosis.
AIM: To evaluate the surgical outcomes of a simplified slipknot pupilloplasty technique for repairing mydriasis, with a focus on postoperative visual recovery, pupil morphological stability, knitting efficiency and knot security. METHODS: This prospective case series included patients with mydriasis due to trauma, glaucoma attack or iatrogenic damage, who underwent pupilloplasty (with or without intraocular lens implantation) from October 2022 to July 2025. Postoperative follow-ups were performed at 1, 3, 6, and 12mo. All cases had a minimum follow-up period of 3mo (range 3–12mo). Parameters recorded included best-corrected visual acuity (BCVA, logMAR), pupil diameter, and intraocular pressure (IOP). RESULTS: A total of 32 consecutive patients (32 eyes, 21 males) were included. The mean age was 57.9±15.9y (21 to 85y). The simplified slipknot technique resulted in significant visual improvement: the mean preoperative logMAR BCVA was 1.15±0.79 (range, 0.22 to 2.5), which improved to 0.35±0.32 (range, 0 to 1.398) postoperatively. Postoperative pupil diameter remained stable, with a mean of 3.0±0.5 mm (range, 2.5 to 4 mm). The duration of the pupilloplasty was 4.3±0.5min and there was no loosening or shedding of the line knot in any case. CONCLUSION: The simplified slipknot technique has a similar treatment effect and safety as the traditional technique but requires a shorter time and is easier to perform in pupilloplasty surgery. It causes minimal trauma to intraocular tissues, and is easy to popularize.
AIM: To investigate the functions of microRNA-26a-5p (miR-26a-5p) in the high glucose (HG)-induced rat retinal Müller cells (rMC-1) apoptosis and its possible mechanism. METHODS: rMC-1 cells were transfected with miR-26a-5p mimics or phosphatase and tensin homolog (PTEN) siRNA under HG conditions. Cell apoptosis was analyzed by propidium iodide (PI) and annexin V fluorescein isothiocyanate (FITC) staining. PTEN/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway activation was assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot. Inflammatory cytokines, interleukin (IL)-1β, IL-6, were measured by enzyme-linked immunosorbent assay (ELISA). The miR-26a-5p-PTEN interaction was validated by dual-luciferase assay. RESULTS: HG significantly suppressed miR-26a-5p expression and induced apoptosis in rMC-1 cells. Overexpression of miR-26a-5p attenuated HG-induced apoptosis by directly targeting PTEN, as confirmed by dual-luciferase reporter assay, which demonstrated that miR-26a-5p directly binds to the PTEN 3’-UTR, resulting in a 50% reduction in luciferase activity (P<0.01). Consistent with this, miR-26a-5p overexpression downregulated PTEN expression, enhanced PI3K/Akt phosphorylation, and suppressed the secretion of IL-1β and IL-6 (all P<0.01). CONCLUSION: Upregulation of miR-26a-5p protects rMC-1 from HG-induced apoptosis by targeting PTEN via regulating the PI3K/Akt pathway and inflammatory responses. miR-26a-5p may be a potential therapeutic target for diabetic retinal neurodegeneration.
AIM: To evaluate the long-term outcomes of anti-vascular endothelial growth factor (VEGF) therapy during cataract surgery in eyes with diabetic macular edema (DME). METHODS: This was a retrospective clinical study. Patients with DME scheduled for cataract surgery were included. Prior to surgery, DME was considered adequately controlled, defined as a central subfield thickness (CST) of ≤300 μm without evidence of significant intraretinal or subretinal fluid on optical coherence tomography. Participants were divided into two groups: 18 patients underwent cataract surgery alone, and 10 received both cataract surgery and anti-VEGF therapy concurrently. The study compared the timing of the initial postoperative anti-VEGF injection and the frequency of injections over 5y. Postoperative outcomes, particularly improvements in best-corrected visual acuity (BCVA) and changes in CST, were also examined. RESULTS: A total of 28 patients were enrolled, with 10 patients undergoing combined cataract surgery and anti-VEGF therapy (3 males, 62.8±4.4y), while 18 patients (7 males, 70.0±13.6y) underwent cataract surgery alone. The combined therapy group had a significantly longer interval before the initial postoperative anti-VEGF injection (12.2±5.7wk) compared to the cataract-only group (4.4±1.6wk). The combined therapy group also required significantly fewer total anti-VEGF injections over 1, 3, and 5y, with the most notable difference in the first year. There was significant improvement in BCVA from pre- to postoperative stages across all eyes. However, there was no statistically significant difference in postoperative BCVA and CST between the groups. CONCLUSION: Concurrent anti-VEGF therapy during cataract surgery is associated with lower early postoperative DME recurrence and a longer interval to the first postoperative anti-VEGF injection. This combined approach may reduce early treatment burden.